Last checked at 
LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.
Clevegen, an anti-Clever-1 antibody, changes the immune environment of tumours by changing suppressive macrophages into active macrophages.
Faron said the filing is a "key" step in its ongoing study into the safety and effectiveness of Clevegen. Cancers under investigation include cutaneous melanoma, pancreatic, ovarian, and colorectal.
Chief Executive Markku Jalkanen said: "We are making rapid progress with our Clevegen programme and this CTA filing is an important milestone.
"This precision therapy for cancers with very few treatment options has a unique mechanism of action which, coupled with promising pre-clinical data and human ex-vivo data, already indicates the product's potential in a broad range of indications. We look forward to beginning patient recruitment later this year and moving Clevegen into the clinic."
Shares were 4.0% higher on Monday at a price of 102.95 pence each.
